hotspot -WSS

hotspot

author：focus 2025-09-28 10:52:50 - browse：3762

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： IVG is promising — but it won’t replace IVF quite yet

WSS

Ancient Greek ideas underpin modern concepts of pregnancy

$1 billion proposal to grow Boston, Massachusetts biotech

With Roe v Wade overturned, abortion providers work to adapt

The biotech scorecard for Q4: 16 stock

The biotech scorecard for Q4: 16 stock

Longer MASH drug regimen improved liver, Akero study finds

focus

hotspot

focus

How one medical school became remarkably diverse

Lack of health data on LGBTQ+ people has serious consequences

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare innovation center doesn’t save money, experts say

Medical records are filled with copy

Lawsuit highlights wrinkle for disputes over surprise medical bills

Duchenne breakthrough therapy leaves behind pioneering families

Why Talkspace is targeting Medicare, a tricky market

At least 13 dead in Texas as scorching temps continue

Experts study whether long Covid risk adds up with each reinfection

focus

Congress extends some pandemic preparedness programs

The stability of $0 premiums in Medicare Advantage

2023 Nobel Prize in Medicine goes to Karikó and Weissman

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Medicare innovation center doesn’t save money, experts say

New oral drug delivery patch is modeled after octopus tentacles

knowledge

entertainment

explore

hotspot